Specification :

Our Indonesian patented anticancer drug-Kanglaite Injection (KLT) has been on top of best selling antineoplastic agents in China with over 600,000 cases with lung, liver, breast, kidney, colon, pancreatic or stomach cancers. Phase I trial in USA, Phase II in Russia and Phase III in China have proven that KLT can directly kill cancer cells and enhance immune capacity, effectively control cancerous pain and cachexia, pain and improve QOL, PPT and MST to prolong patient life with very little side effect.

We are seeking an Indonesian sole agent to register KLT at MOH to be followed by importation and distrubution.

Serious and professional company preferably in oncological line are welcome to contact us. Visit: ww.kanglaite.com for product information and clinical publications. Thanks.

Christopher Li, Director
Kanglaite International,
Zhejiang Kanglaite Pharmaceutical Co., Ltd.
Phone: +86-571-86911888 ext 1207/1209
Fax: +86-571-86911680
Email: kanglaite@yahoo.com.cn